BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17023783)

  • 1. Computed tomography (CT) scan evaluation of late toxicity following hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) in breast cancer patients treated with conservative surgery.
    Manavis J; Ambatzoglou J; Sismanidou K; Koukourakis MI
    Am J Clin Oncol; 2006 Oct; 29(5):479-83. PubMed ID: 17023783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
    Koukourakis MI
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computed tomography assessment of lung density in patients with lung cancer treated with accelerated hypofractionated radio-chemotherapy supported with amifostine.
    Koukourakis MI; Tsoutsou PG; Abatzoglou I
    Am J Clin Oncol; 2009 Jun; 32(3):258-61. PubMed ID: 19349852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of low-risk prostate cancer with radical hypofractionated accelerated radiotherapy with cytoprotection (HypoARC): an interim analysis of toxicity and efficacy.
    Koukourakis MI; Kyrgias G; Papadopoulou A; Panteliadou M; Giatromanolaki A; Sivridis E; Mavropoulou S; Kalogeris K; Nassos P; Milioudis N; Touloupidis S
    Anticancer Res; 2011 May; 31(5):1745-51. PubMed ID: 21617234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
    Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
    Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer.
    Koukourakis MI; Tsoutsou PG; Abatzoglou I; Soulimioti G; Sismanidou K; Liberis V; Giatromanolaki A; Sivridis E; Galazios G
    Tumori; 2009; 95(4):455-60. PubMed ID: 19856656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: rationale, technique and early experience.
    Koukourakis MI; Touloupidis S; Manavis J; Abatzoglou I; Sismanidou K; Sivridis L
    Anticancer Res; 2004; 24(5B):3239-43. PubMed ID: 15510617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
    Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
    Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
    Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
    Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
    Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
    Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated hypofractionated radiotherapy as adjuvant regimen after conserving surgery for early breast cancer: interim report of toxicity after a minimum follow up of 3 years.
    PinnarĂ² P; Soriani A; Landoni V; Giordano C; Papale M; Marsella A; Marucci L; Arcangeli G; Strigari L
    J Exp Clin Cancer Res; 2010 Jan; 29(1):9. PubMed ID: 20100335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC).
    Panteliadou M; Giatromanolaki A; Touloupidis S; Destouni E; Tsoutsou PG; Pantelis P; Abatzoglou I; Sismanidou K; Koukourakis MI
    Urol Oncol; 2012; 30(6):813-20. PubMed ID: 21163674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer.
    Koukourakis MI; Manavis J; Simopoulos C; Liberis V; Giatromanolaki A; Sivridis E
    Am J Clin Oncol; 2005 Oct; 28(5):495-500. PubMed ID: 16199990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy.
    De Santis MC; Bonfantini F; Di Salvo F; Dispinzieri M; Mantero E; Soncini F; Baili P; Sant M; Bianchi G; Maggi C; Di Cosimo S; Agresti R; Pignoli E; Valdagni R; Lozza L
    Breast; 2016 Oct; 29():90-5. PubMed ID: 27476083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.